Genitourinary Cancers

Alexander Chehrazi-Raffle, MD, discusses findings from an exploratory analysis of the TiNivo-2 trial of tivozanib with/without nivolumab in metastatic RCC.

Naomi B. Haas, MD, discusses safety data from the phase 3 KEYNOTE-564 trial of adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.

A research fellow from Dana-Farber Cancer Institute shares post hoc findings from the phase 3 JAVELIN Renal 101 trial.

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

Alexander Chehrazi-Raffle, MD, discusses the efficacy of tivozanib monotherapy after receipt of upfront IO/TKI or ipilimumab/nivolumab in RCC.

ALLO-316 showed activity and a tolerable safety profile in patients with pretreated advanced or metastatic clear cell renal cell carcinoma.

Naomi B. Haas, MD, delves into the KEYNOTE-564 trial and highlights the role of adjuvant pembrolizumab in clear cell renal cell carcinoma.

Sumanta Kumar Pal, MD, FASCO, discusses the genomic activity of adjuvant atezolizumab vs placebo in patients with high-risk resected RCC.

Alan Tan, MD, emphasizes the importance of considering safety profiles and patient-related factors before selecting an IO regimen in metastatic ccRCC.

A new drug application seeking the Chinese approval of sintilimab plus fruquintinib in second-line advanced/metastatic RCC has been accepted by the NMPA

The evaluation of diverse biomarkers via a machine learning approach demonstrated improved prediction of clinical outcomes vs individual biomarkers in RCC.

Tivozanib monotherapy was effective and outperformed tivozanib plus nivolumab after receipt of upfront IO/TKI or ipilimumab/nivolumab regimens in RCC.

Cabozantinib plus atezolizumab or cabozantinib alone was effective regardless of prior immunotherapy or TKI treatment in second-line advanced RCC.

Adjuvant pembrolizumab showed maintained OS and DFS vs placebo in patients with ccRCC at the 5-year analysis.

First-line nivolumab/ipilimumab demonstrated sustained survival signals and responses vs sunitinib in previously untreated advanced RCC.

Nivolumab has been approved for subcutaneous use across several adult solid tumor indications that have an existing indication for intravenous use.

Ahead of the 2025 ASCO Annual Meeting, experts in genitourinary cancers share the most anticipated research being presented during the meeting.

Scott Tykodi, MD, PhD, discusses the challenges with developing effective, less toxic triplet regimens for patients with advanced RCC.

During an OncLive Peer Exchange filmed during ASCO GU, expert investigators discussed significant updates in the RCC space.

Evan T. Hall, MD, Mphil, discusses several avenues for future research in later-line renal cell carcinoma.

Kathryn E. Beckerman, MD, PhD, details the rationale for evaluating tivozanib/nivolumab following immune checkpoint inhibitors in renal cell carcinoma.

Sitravatinib plus nivolumab did not produce significant antitumor activity or survival outcomes in patients with progressive metastatic clear cell RCC.

Belzutifan was safe and effective in patients with von Hippel-Lindau–associated RCC and other neoplasms.

Evan T. Hall, MD, MPhil, discusses the limited potential for immunotherapy rechallenge in patients with RCC and challenges with later-line RCC management.

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.